6.5 C
New York
Saturday, October 23, 2021

Molnupiravir: A cure for early COVID-19 treatment, results are encouraging

Must Read

CDC: More than 35% of people hospitalized with Delta variant are between 18-to-49

The CDC researchers attribute the shift in the age of patients diagnosed with the virus to decreased...

Unvaccinated Tennessee woman dies of COVID-19 after giving birth prematurely

Pregnant women are one of the least vaccinated groups in the United States, despite the fact that...

Prop Gun used by Alec Baldwin in deadly accident ‘had been declared safe to use’

The prop gun used by Alec Baldwin in a tragic shooting accident on a film set was...
Kamal Saini
Kamal S. has been Journalist and Writer for Business, Hardware and Gadgets at Revyuh.com since 2018. He deals with B2b, Funding, Blockchain, Law, IT security, privacy, surveillance, digital self-defense and network policy. As part of his studies of political science, sociology and law, he researched the impact of technology on human coexistence. Email: kamal (at) revyuh (dot) com

Scientists from US drugmaker MSD have found that the experimental drug Molnupiravir reduces the level of infectious virus in the early stages of the disease.

An experimental drug for the treatment of coronavirus is being tested in the United States, which has been shown to be highly effective at an early stage of the disease during testing.

It is reported that the drug molnupiravir showed a rapid decrease in the level of infectious virus in patients at an early stage of the disease.

The drug was tested in more than 200 hospitalized patients, all of whom had faster reductions in viral infectivity than those in the placebo group.

“We are very pleased to share our initial Phase 2 infectivity data at this important conference, which remains at the forefront for critical clinical scientific information in infectious diseases”

shared Dr. Wendy Painter, Chief Medical Officer of Ridgeback Biotherapeutics.

“At a time where there is unmet need for antiviral treatments against SARS-CoV-2, we are encouraged by these preliminary data.”

Dr William Fischer, a leading researcher at the University of North Carolina School of Medicine, called the research results promising, but more research needs to confirm them.

“The secondary objective findings in this study, of a quicker decrease in infectious virus among individuals with early COVID-19 treated with molnupiravir, are promising and if supported by additional studies, could have important public health implications, particularly as the SARS-CoV-2 virus continues to spread and evolve globally”

noted Dr. William Fischer.

Molnupiravir is an experimental oral antiviral agent developed for the treatment of influenza.

- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -